MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Evolus Interest Expense 2011-2026 | EOLS
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Evolus
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127 K | 696 K | -9 K | 1.4 M | -10.5 M | -7.95 M | 863 K | 5 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.4 M | -10.5 M | -1.92 M |
Quarterly Interest Expense Evolus
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -455 K | -151 K | 57 K | - | 273 K | 62 K | 45 K | - | 21 K | 19 K | 2.79 M | - | 2.34 M | 2.08 M | 2.05 M | - | 311 K | -300 K | 645 K | - | -2.76 M | -2.46 M | -2.46 M | - | -2.46 M | -2.41 M | -618 K | - | -322 K | -321 K | 107 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.79 M | -2.76 M | -163 K |
Interest Expense of other stocks in the Drug manufacturers industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
10.2 M | - | - | $ 142 M |  USA |
 |
Canopy Growth Corporation
CGC
|
74.6 M | $ 1.18 | 3.07 % | $ 127 M |  Canada |
 |
Aerie Pharmaceuticals
AERI
|
-27.9 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
1.12 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.92 K | - | 0.86 % | $ 117 M | USA |
 |
Catalent
CTLT
|
-4 M | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
1.42 M | - | 10.11 % | $ 58.2 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
4.04 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
350 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
500 K | - | - | $ 36.6 M | USA |
 |
DURECT Corporation
DRRX
|
2.24 M | - | - | $ 50.1 M | USA |
 |
HEXO Corp.
HEXO
|
20.1 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Emergent BioSolutions
EBS
|
87.9 M | $ 12.3 | -0.49 % | $ 630 M | USA |
 |
Jupiter Wellness
JUPW
|
-5.37 M | - | - | $ 33.6 M | USA |
 |
Athenex
ATNX
|
25.8 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
13 M | $ 21.52 | -0.14 % | $ 2.05 B |  France |
 |
Organogenesis Holdings
ORGO
|
20 K | $ 4.92 | -5.01 % | $ 648 M | USA |
 |
Pacira BioSciences
PCRX
|
-373 K | $ 25.08 | -3.09 % | $ 1.16 B | USA |
 |
Harrow Health
HROW
|
21.3 M | $ 47.88 | -2.29 % | $ 1.56 B | USA |
 |
China Pharma Holdings
CPHI
|
27.4 K | $ 1.23 | 1.64 % | $ 21.5 M |  China |
 |
Sundial Growers
SNDL
|
81 K | $ 1.68 | 1.14 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-10 K | $ 3.57 | -1.8 % | $ 4.43 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
12 K | - | - | $ 193 M | Canada |
 |
Bausch Health Companies
BHC
|
-28 M | $ 6.98 | 0.43 % | $ 2.55 B | Canada |
 |
Lannett Company
LCI
|
58 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
606 K | $ 3.85 | -3.27 % | $ 54.1 M | USA |
 |
Veru
VERU
|
862 K | $ 2.18 | 1.87 % | $ 294 M | USA |
 |
Radius Health
RDUS
|
18.3 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
2.3 M | $ 0.86 | 1.99 % | $ 20.1 M | USA |
 |
PetIQ
PETQ
|
38.3 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
900 K | $ 13.86 | -0.47 % | $ 1.9 B | USA |
 |
ProPhase Labs
PRPH
|
764 K | $ 0.45 | 0.36 % | $ 7.13 M | USA |
 |
cbdMD
YCBD
|
-29.5 K | $ 1.16 | -14.44 % | $ 5 M | USA |
 |
Recro Pharma
REPH
|
9.96 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.15 M | $ 4.55 | -5.8 % | $ 137 M | USA |
 |
OptiNose
OPTN
|
19.5 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
2.78 M | $ 9.3 | 2.54 % | $ 661 M | USA |
 |
Solid Biosciences
SLDB
|
652 K | $ 5.49 | -2.66 % | $ 224 M | USA |
 |
SCYNEXIS
SCYX
|
3.13 M | $ 0.62 | -1.96 % | $ 29.7 M | USA |
 |
Tricida
TCDA
|
17.6 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
46.6 M | $ 9.43 | 4.37 % | $ 5.83 B | Canada |
 |
TherapeuticsMD
TXMD
|
300 K | $ 1.62 | -0.61 % | $ 16.9 M | USA |
 |
Viatris
VTRS
|
592 M | $ 12.36 | -0.76 % | $ 15 B | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
80.2 K | - | - | $ 55.5 M | USA |